PDA

View Full Version : Dissolution Discussion


Pages : 1 2 3 4 5 6 7 8 [9]

  1. When not to perform dissolutions
  2. Validation on ER Tablets
  3. Method Development Dearation Set-Up
  4. Waiver of In-vivo Bioavailability and Bioequivalence Studies
  5. Calibration Curve
  6. Method Development Dissolution results in higher side
  7. Regulatory Discussion Multimedia Dissolution
  8. Anyone have dissolution presentation?
  9. Dissolution Theory Reciprocating Cylinder (USP-III)
  10. Regulatory Discussion Profile similarity
  11. dissolution media for Extended release
  12. Calibration fixed positions for vessels?!!
  13. Method Development simultaneous analysis of Metformin and Glimepiride in dissolution samples by HPLC
  14. Using sinker in the dissolution of carvedilol tablets
  15. Method Development Bupropion HCl dissolution hiher side
  16. General Lysine Acetylsalicylate Analytical Methodology
  17. Dissolution Theory Sample protocol
  18. Method Development Simulated intestinal fluid
  19. Method Development Dissolution Medium for glimepiride /metformin HCl combination tablets
  20. Dissolution Behavior of Microcrystalline Cellulose
  21. Regulatory Discussion Dissolution sampling
  22. Dissolution Theory diffrent dosage form
  23. S.o.s
  24. Apparatus 7
  25. Dissolution Testing - Future
  26. Please help
  27. General Powder dissolution with USP IV
  28. Method Development different baskets
  29. Validation Er tablets - method precision
  30. A simple QC approach
  31. General Enzyme Conversion unit
  32. Solubility determinations
  33. Method Development Transdermal Systems-Selection of media/volume
  34. F2 evaluation and BE possibility
  35. Apparatus 4
  36. Dissolution media for poorly solble drugs
  37. Method Development Oil Soluble vitamins
  38. General Dissolution method for voglibose
  39. Pantoprazole E/C Tab dissolution
  40. Calibration Mechanical calibration
  41. Method Development In-Vitro release for suspensions
  42. Dissolution Theory Fixing of specification limit in dissolution
  43. General Dissolution method development
  44. General Number of time points for a dissolution profile
  45. General Dissolution Method Change
  46. New change to pvt
  47. Tacrolimus
  48. Method Development Franz diffusion
  49. Sublingual tablets
  50. Dissolution Theory Cholecalciferol(Vitamin D3) Dissolution method
  51. Method Development Delayed release systems
  52. General USP requirement for sinkers
  53. pH of hydrogel transdermal system
  54. Calibration FIP position concerning FDA draft guidance for mechanical calibration
  55. Dissolution Problem in LOsartan + Hydrochlorothiazide Tablet
  56. Method Development amtolmetin
  57. Dissolution Theory prodrug
  58. General selecting of franz cell membrane
  59. Method Development Dissolution of Practically insoluble drug
  60. Itraconazole Dissolution
  61. Troubleshooting Effect of RPM on Extended Release
  62. Dissolution Theory nitaxozanide disolution
  63. Calibration MQ testing
  64. Limit for start the test
  65. Dissolution Media
  66. Method Development Telmisartan/Hydrochlorothiazid
  67. General Use of Organic Solvent in dissolution medium
  68. Method Development Rational use of Sinkers
  69. General Dissolution Method
  70. Method Development What flow rate and time interval usually used for slow release drug using USP 4
  71. New Revelation
  72. Method Development Excipients trapped inside baskets @ 50 rpm’s
  73. Regulatory Discussion Dissolution rate calculation: based on label claim or assay?
  74. Apparatus 3 calibration using 1L vessels?
  75. Assay procedures for vitamins
  76. Method Development Haziness of Phosphate Buffers
  77. Method Development Dissolution medium for Rabeprazole Delayed Release Tablets
  78. General Dissolution Standard preparation
  79. Placebo Effect Getting Stronger
  80. Dissolution for 4 weeks
  81. Regulatory Discussion Functional Coating weight gain not weight proportional
  82. Troubleshooting Lansoprazole dissolution and degradation
  83. The dissolution method of tab contain Papaverine, Metamizole, Belladonne
  84. enzimes in Eu.Pharm.
  85. Dissolution Theory monograph tolerance limit of irbesartan dissolution
  86. Method Development Dissolution of Valsartan Immediate release Tablets
  87. Poorly soluble capsules
  88. Troubleshooting Tablets dissolution rate slow down over time?
  89. General Biorelevant medias / Physiological mediums
  90. Calibration status of the mechanical check
  91. Phosphate or Acetate buffer pH 4.5
  92. SLS inhibits Enzyme?
  93. General Quetiapine extended release tablet
  94. Transit time in Small intestine and medium
  95. Validation Validating the range of a method
  96. Dissolution Theory HPC Role in Dissolution media
  97. Method Development App 7 with OE Tablets
  98. Maximum Limits for Surfactant in Dissolution Media
  99. Quetiapine and solubility class
  100. Calibration Mechanical Calibration
  101. Choose of mediums for comparative dissolution profiles (f2)
  102. Acetate Buffer as dissolution media
  103. Cyclosporine A Dissolution Medium
  104. validation of Tier II method
  105. Troubleshooting Lipidic semisolid formulation
  106. Troubleshooting Variables in the dissolution results
  107. Validation Intermediate precision - modified release
  108. dissolution with SGF
  109. When to use disintegration disks
  110. Tris Buffer pH 4.0
  111. Nifuroxazide
  112. Metformin baskets
  113. Regulatory Discussion Target Dissolution Rate for Extended Release Dosage Forms
  114. General Degradation in certain recomended media during dissolution comparative studies
  115. General Coning Effect issues on biorelevant medium
  116. Sink conditions with surfactants
  117. Media incompatibility
  118. Regulatory aspects- Atorvastatin
  119. Cameras for monitoring automated runs
  120. Lacticin by HPLC
  121. Calibration Salicyclic acid PVT
  122. Basket Integrity verification
  123. App 5 or Ring/Mesh with Small Volume Dissolution?
  124. Method Development Extended release development
  125. Method Development Drug release: subcut implant
  126. Which Calibration Type are you using?
  127. Method Development Re-crystallization / precipitation of API during dissolution test.
  128. Method Development Does Pancreatin precipitate with SLS
  129. media for Glyburide in Metformin+Glyburide
  130. Mishapen/damaged baskets
  131. Automated degassing
  132. dissolution for injectable suspensions
  133. Method Development Dissolution media clarification
  134. Formation of chelates help me...
  135. Sampling procedure for apparatus 6 (cylinder)
  136. Regulatory Discussion dissolution comparison for suppositories
  137. controlled release tablet dosage form
  138. Disposal of dissolution medium
  139. Dissolution Theory Pantoprazol sodium Enteric Coated Tablet Dissolution
  140. Dissolution Theory SLS and Biorelevant Properties for Thiocolchicoside
  141. Level A IVIVC for biphasic product
  142. Dissolution testing for IR in oil formulation
  143. Tier 2 dissolution medium pH with pepsin
  144. General Manual Sampling: Fresh syringe filter each time-point or one for each Vessel?
  145. Non-standard dissolution media: HEPES and MOPS
  146. General Oral Suspensions
  147. Dissolution Theory Maximum level of SLS in diso media???
  148. Regulatory Discussion Changes to the Dissolution Performance Verification test
  149. Batch size for IVIVC development
  150. assay limit acc to ICH guideline
  151. F2 value and ANDA submission
  152. Using Paddle over disk method for Tablets
  153. Method Development Citro phosphate buffer
  154. FDA's January 2010 Guidance on bath Calibration
  155. Validation Diss. Method Re-validation
  156. enzyme and soft gelatin capsules
  157. Programming for Autosampling
  158. Regulatory Discussion Changing disso medium
  159. salt precipitation in my PBS buffer
  160. Early time point > 100 % - Filtration issue
  161. Usage of sinkers for IR tablet formulation
  162. Dissolution of Phenylephrine and Terfenadine
  163. Regulatory Discussion Omeprazole (Prilosec) and BCS
  164. Eudragit NE
  165. General TRUE Borelevant dissolution medium/dissolution condition
  166. Troubleshooting Impact of Magnesium oxide on drug release upon storage
  167. Dissolution Theory 3 media disolution for Class 1 molecule
  168. Regulatory Discussion New EMEA guidelines BA/BE
  169. Dissolution Theory Minimum requirement for Dissolution
  170. General Disintegration testing of novel dosage form
  171. PVT - Calculation Tool
  172. Total dissolved gas pressure meter
  173. Method Development Modified Release Tablets
  174. Method Development Cutting caplet for dissolution
  175. Very high CV for Fast dissolving tablet
  176. Database Corruption / Missing Posts & Registrations
  177. Calibration Are basket and paddle position important?
  178. Troubleshooting Dissolution media degasing for extended release formulation dosage form
  179. Dissolution Theory Model Independent multivariate confidence region procedure
  180. different types of dissolution medium
  181. Method Development Reciprocating Cylinder - Apparatus III
  182. Method Development pramipexole
  183. change of mesh size in basket for dissolution
  184. Regulatory Discussion Data to support a request for Biowaiver
  185. Non Ionic Surfactants?
  186. Regulatory Discussion Drug Stability and Comparative in vitro Dissolution